Infinity Pharmaceuticals, Inc. financial data

Symbol
INFIQ on OTC
Industry
Pharmaceutical Preparations
Location
1100 Massachusetts Avenue, Floor 4, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
DISCOVERY PARTNERS INTERNATIONAL INC (to 9/11/2006)
Latest financial report
10-Q - Q2 2023 - Aug 10, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 269 % -52.7%
Debt-to-equity -252 % -163%
Return On Equity 171 %
Return On Assets -113 % -89.5%
Operating Margin -1.64K % +22.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8M shares +1.66%
Common Stock, Shares, Outstanding 90.8M shares +1.66%
Entity Public Float 55M USD -78.8%
Common Stock, Value, Issued 90K USD +1.12%
Weighted Average Number of Shares Outstanding, Basic 89.9M shares +0.81%
Weighted Average Number of Shares Outstanding, Diluted 89.9M shares +0.81%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.57M USD +15.9%
Research and Development Expense 27.1M USD -18.6%
General and Administrative Expense 16M USD +12%
Operating Income (Loss) -42M USD +9.92%
Nonoperating Income (Expense) 1.1M USD +413%
Net Income (Loss) Attributable to Parent -40.9M USD +12.5%
Earnings Per Share, Basic -0.46 USD/shares +11.5%
Earnings Per Share, Diluted -0.46 USD/shares +11.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD -61.3%
Other Assets, Current 377K USD -3.09%
Assets, Current 19.9M USD -66.6%
Property, Plant and Equipment, Net 589K USD -42.1%
Operating Lease, Right-of-Use Asset 493K USD -44.4%
Other Assets, Noncurrent 84K USD -54.6%
Assets 21.2M USD -65.7%
Accounts Payable, Current 1.5M USD -17.2%
Employee-related Liabilities, Current 1.22M USD -46.5%
Liabilities, Current 12.1M USD -15.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 58.6M USD -6.87%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18K USD
Retained Earnings (Accumulated Deficit) -877M USD -4.9%
Stockholders' Equity Attributable to Parent -37.4M USD -3279%
Liabilities and Equity 21.2M USD -65.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.6M USD +7.09%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 90.8M shares +1.66%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.6M USD +54.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD -61.1%
Deferred Tax Assets, Valuation Allowance 256M USD +4.93%
Operating Lease, Liability 917K USD -36.1%
Depreciation 105K USD -13.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.9M USD +12.6%
Lessee, Operating Lease, Liability, to be Paid 700K USD -46.2%
Property, Plant and Equipment, Gross 4.11M USD +0.42%
Operating Lease, Liability, Current 633K USD +14.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 334K USD -49.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 658K USD +2.81%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 75K USD -61.7%
Deferred Tax Assets, Operating Loss Carryforwards 171M USD +3.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.57M USD +43.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%